217 related articles for article (PubMed ID: 31387987)
1. Mutational processes contributing to the development of multiple myeloma.
Hoang PH; Cornish AJ; Dobbins SE; Kaiser M; Houlston RS
Blood Cancer J; 2019 Aug; 9(8):60. PubMed ID: 31387987
[TBL] [Abstract][Full Text] [Related]
2. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.
Walker BA; Wardell CP; Murison A; Boyle EM; Begum DB; Dahir NM; Proszek PZ; Melchor L; Pawlyn C; Kaiser MF; Johnson DC; Qiang YW; Jones JR; Cairns DA; Gregory WM; Owen RG; Cook G; Drayson MT; Jackson GH; Davies FE; Morgan GJ
Nat Commun; 2015 Apr; 6():6997. PubMed ID: 25904160
[TBL] [Abstract][Full Text] [Related]
3. Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis.
Petljak M; Alexandrov LB; Brammeld JS; Price S; Wedge DC; Grossmann S; Dawson KJ; Ju YS; Iorio F; Tubio JMC; Koh CC; Georgakopoulos-Soares I; Rodríguez-Martín B; Otlu B; O'Meara S; Butler AP; Menzies A; Bhosle SG; Raine K; Jones DR; Teague JW; Beal K; Latimer C; O'Neill L; Zamora J; Anderson E; Patel N; Maddison M; Ng BL; Graham J; Garnett MJ; McDermott U; Nik-Zainal S; Campbell PJ; Stratton MR
Cell; 2019 Mar; 176(6):1282-1294.e20. PubMed ID: 30849372
[TBL] [Abstract][Full Text] [Related]
4. Unravelling the Sequential Interplay of Mutational Mechanisms during Clonal Evolution in Relapsed Pediatric Acute Lymphoblastic Leukemia.
Antić Ž; Lelieveld SH; van der Ham CG; Sonneveld E; Hoogerbrugge PM; Kuiper RP
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33540666
[TBL] [Abstract][Full Text] [Related]
5. APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.
Cho RJ; Alexandrov LB; den Breems NY; Atanasova VS; Farshchian M; Purdom E; Nguyen TN; Coarfa C; Rajapakshe K; Prisco M; Sahu J; Tassone P; Greenawalt EJ; Collisson EA; Wu W; Yao H; Su X; Guttmann-Gruber C; Hofbauer JP; Hashmi R; Fuentes I; Benz SC; Golovato J; Ehli EA; Davis CM; Davies GE; Covington KR; Murrell DF; Salas-Alanis JC; Palisson F; Bruckner AL; Robinson W; Has C; Bruckner-Tuderman L; Titeux M; Jonkman MF; Rashidghamat E; Lwin SM; Mellerio JE; McGrath JA; Bauer JW; Hovnanian A; Tsai KY; South AP
Sci Transl Med; 2018 Aug; 10(455):. PubMed ID: 30135250
[TBL] [Abstract][Full Text] [Related]
6. Mutational spectra and mutational signatures: Insights into cancer aetiology and mechanisms of DNA damage and repair.
Phillips DH
DNA Repair (Amst); 2018 Nov; 71():6-11. PubMed ID: 30236628
[TBL] [Abstract][Full Text] [Related]
7. Integrative genomic analysis identifies associations of molecular alterations to APOBEC and BRCA1/2 mutational signatures in breast cancer.
Trevino V
Mol Genet Genomic Med; 2019 Aug; 7(8):e810. PubMed ID: 31294536
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics.
Shen P; Jing Y; Zhang R; Cai MC; Ma P; Chen H; Zhuang G
Oncogene; 2018 May; 37(22):3039-3044. PubMed ID: 29535424
[TBL] [Abstract][Full Text] [Related]
9. Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group.
Samur MK; Aktas Samur A; Fulciniti M; Szalat R; Han T; Shammas M; Richardson P; Magrangeas F; Minvielle S; Corre J; Moreau P; Thakurta A; Anderson KC; Parmigiani G; Avet-Loiseau H; Munshi NC
J Clin Oncol; 2020 Sep; 38(27):3107-3118. PubMed ID: 32687451
[TBL] [Abstract][Full Text] [Related]
10. Network-based approaches elucidate differences within APOBEC and clock-like signatures in breast cancer.
Kim YA; Wojtowicz D; Sarto Basso R; Sason I; Robinson W; Hochbaum DS; Leiserson MDM; Sharan R; Vadin F; Przytycka TM
Genome Med; 2020 May; 12(1):52. PubMed ID: 32471470
[TBL] [Abstract][Full Text] [Related]
11. A framework for mutational signature analysis based on DNA shape parameters.
Karolak A; Levatić J; Supek F
PLoS One; 2022; 17(1):e0262495. PubMed ID: 35015788
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.
Walker BA; Mavrommatis K; Wardell CP; Ashby TC; Bauer M; Davies FE; Rosenthal A; Wang H; Qu P; Hoering A; Samur M; Towfic F; Ortiz M; Flynt E; Yu Z; Yang Z; Rozelle D; Obenauer J; Trotter M; Auclair D; Keats J; Bolli N; Fulciniti M; Szalat R; Moreau P; Durie B; Stewart AK; Goldschmidt H; Raab MS; Einsele H; Sonneveld P; San Miguel J; Lonial S; Jackson GH; Anderson KC; Avet-Loiseau H; Munshi N; Thakurta A; Morgan GJ
Blood; 2018 Aug; 132(6):587-597. PubMed ID: 29884741
[TBL] [Abstract][Full Text] [Related]
13. Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC.
Messerschmidt C; Obermayer B; Klinghammer K; Ochsenreither S; Treue D; Stenzinger A; Glimm H; Fröhling S; Kindler T; Brandts CH; Schulze-Osthoff K; Weichert W; Tinhofer I; Klauschen F; Keilholz U; Beule D; Rieke DT
Int J Cancer; 2020 Oct; 147(8):2293-2302. PubMed ID: 32468570
[TBL] [Abstract][Full Text] [Related]
14. Association of mutation signature effectuating processes with mutation hotspots in driver genes and non-coding regions.
Wong JKL; Aichmüller C; Schulze M; Hlevnjak M; Elgaafary S; Lichter P; Zapatka M
Nat Commun; 2022 Jan; 13(1):178. PubMed ID: 35013316
[TBL] [Abstract][Full Text] [Related]
15. Timing the initiation of multiple myeloma.
Rustad EH; Yellapantula V; Leongamornlert D; Bolli N; Ledergor G; Nadeu F; Angelopoulos N; Dawson KJ; Mitchell TJ; Osborne RJ; Ziccheddu B; Carniti C; Montefusco V; Corradini P; Anderson KC; Moreau P; Papaemmanuil E; Alexandrov LB; Puente XS; Campo E; Siebert R; Avet-Loiseau H; Landgren O; Munshi N; Campbell PJ; Maura F
Nat Commun; 2020 Apr; 11(1):1917. PubMed ID: 32317634
[TBL] [Abstract][Full Text] [Related]
16. Mutational signatures reveal ternary relationships between homologous recombination repair, APOBEC, and mismatch repair in gynecological cancers.
Farmanbar A; Firouzi S; Kneller R; Khiabanian H
J Transl Med; 2022 Feb; 20(1):65. PubMed ID: 35109853
[TBL] [Abstract][Full Text] [Related]
17. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines.
Maura F; Petljak M; Lionetti M; Cifola I; Liang W; Pinatel E; Alexandrov LB; Fullam A; Martincorena I; Dawson KJ; Angelopoulos N; Samur MK; Szalat R; Zamora J; Tarpey P; Davies H; Corradini P; Anderson KC; Minvielle S; Neri A; Avet-Loiseau H; Keats J; Campbell PJ; Munshi NC; Bolli N
Leukemia; 2018 Apr; 32(4):1044-1048. PubMed ID: 29209044
[No Abstract] [Full Text] [Related]
18. Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing.
Guo G; Raje NS; Seifer C; Kloeber J; Isenhart R; Ha G; Yee AJ; O'Donnell EK; Tai YT; Richardson PG; Bianchi G; Laubach JP; Warren D; Gemme E; Voisine J; Frede J; Kokkalis A; Yun H; Dimitrova V; Vijaykumar T; Meyerson M; Munshi NC; Anderson KC; Knoechel B; Lohr JG
Leukemia; 2018 Aug; 32(8):1838-1841. PubMed ID: 29749395
[No Abstract] [Full Text] [Related]
19. A practical guide for mutational signature analysis in hematological malignancies.
Maura F; Degasperi A; Nadeu F; Leongamornlert D; Davies H; Moore L; Royo R; Ziccheddu B; Puente XS; Avet-Loiseau H; Campbell PJ; Nik-Zainal S; Campo E; Munshi N; Bolli N
Nat Commun; 2019 Jul; 10(1):2969. PubMed ID: 31278357
[TBL] [Abstract][Full Text] [Related]
20. Two main mutational processes operate in the absence of DNA mismatch repair.
Németh E; Lovrics A; Gervai JZ; Seki M; Rospo G; Bardelli A; Szüts D
DNA Repair (Amst); 2020 May; 89():102827. PubMed ID: 32126497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
